Pulmonary Arterial Hypertension With Who Functional Class Ii Or Iii Therapeutics
1. Opsumit patent expiration
Treatment: Method of treating pulmonary hypertension comprising administering macitentan in combination with a compound having phosphodiesterase-5 inhibitory properties; Method of treating pulmonary arterial hyp...
OPSUMIT IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7094781 | ACTELION | Sulfamides and their use as endothelin receptor antagonists |
Dec, 2025
(a month ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8268847 | ACTELION | Therapeutic compositions comprising a specific endothelin receptor antagonist and a PDE5 inhibitor |
Apr, 2029
(3 years from now) | |
| US9265762 | ACTELION | Stable pharmaceutical compositions comprising a pyrimidine-sulfamide |
May, 2027
(1 year, 4 months from now) | |
| US10946015 | ACTELION | Stable pharmaceutical compositions comprising a pyrimidine-sulfamide |
Sep, 2026
(8 months from now) | |
| US8367685 | ACTELION | Stable pharmaceutical compositions comprising a pyrimidine-sulfamide |
Oct, 2028
(2 years from now) | |
|
US8268847 (Pediatric) | ACTELION | NA |
Oct, 2029
(3 years from now) | |
|
US7094781 (Pediatric) | ACTELION | NA |
Jun, 2026
(4 months from now) | |
|
US8367685 (Pediatric) | ACTELION | NA |
Apr, 2029
(3 years from now) | |
|
US9265762 (Pediatric) | ACTELION | NA |
Nov, 2027
(1 year, 10 months from now) | |
|
US10946015 (Pediatric) | ACTELION | NA |
Mar, 2027
(1 year, 2 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 18, 2018 |
| Orphan Drug Exclusivity(ODE) | Oct 18, 2020 |
| Orphan Drug Exclusivity(ODE-54) | Oct 18, 2020 |
| M(M-187) | Feb 28, 2028 |
| Pediatric Exclusivity(PED) | Aug 28, 2028 |
Drugs and Companies using MACITENTAN ingredient
NCE-1 date: 29 August, 2027
Market Authorisation Date: 18 October, 2013
Dosage: TABLET
How can I launch a generic of OPSUMIT before it's drug patent expiration?
More Information on Dosage
OPSUMIT family patents
